



Joint Working Executive Summary

title	Introduction of a Clinical Pharmacist into the Headache service at South Tyneside & Sunderland NHS Foundation Trust (ST&S NHSFT), who will become part of a multi-disciplinary team.
Project partners	South Tyneside & Sunderland NHS Foundation Trust (ST&S NHSFT) & Allergan (an AbbVie company)
Project summary	<p>This is a project aimed at increasing skill mix within the headache service within ST&S NHSFT through the appointment of a Clinical Pharmacist funded by Allergan for a one- year period and a further year being funded by ST&S NHSFT (subject to approval).</p> <p>Objectives for headache Clinical Pharmacist clinics:</p> <ul style="list-style-type: none"> • Improve patient access to treatments by increasing the number of headache treatment injection appointments available. • Decrease the existing waiting time for new patients who have been recommended for treatment. • Deliver a high-quality service, reflected in audit via PREMs. • The PREMS data to be published by the Trust with the wider headache community. • Expand the headache specialist clinical skill set within the team. • Ongoing development of the Clinical Pharmacist skills in relation to the treatment and management of headache.

<p>Expected benefits to patients, the NHS and Allergan</p>	<p>Benefits to Patients:</p> <ul style="list-style-type: none"> • Patients will benefit from the input of a Clinical Pharmacist, who can support around use of existing treatments. • Improved access to treatment in line with NICE TA 260 guidance. • Improvement in patient quality of life • Better patient understanding of how to manage their condition with emphasis on medicines optimisation. <p>Benefits to NHS:</p> <ul style="list-style-type: none"> • Appointment of the Clinical Pharmacist will increase skill mix within the team. • Appointment of the Clinical Pharmacist will increase capacity to reduce waiting time. • Patients will continue to receive expert care in line with NICE TA 260 guidelines. <p>Benefits to Allergan:</p> <ul style="list-style-type: none"> • Improved patient access to headache injection services via increased capacity, supported by appropriate evaluation, treatment and prescribing in accordance with relevant NICE TA 260 guidance. • Collaboration will benefit all partners through ST&S NHSFT and Allergan’s ability to work in partnership within the NHS environment to benefit patient outcomes and experience.
<p>Start Date</p>	<p>Funded by Allergan (an AbbVie Company) August 2021</p>